At BPGbio Inc, we are actively working to develop a new treatment for Epidermolysis Bullosa (EB), and we are excited about the potential impact it could have on patients’ lives.

What is Epidermolysis Bullosa (EB)?

EB is a rare, connective tissue disorder with many genetic and symptomatic variations characterized by extremely fragile skin and the development of recurrent, painful blisters, open sores, disfiguring scars, disabling musculoskeletal deformities, internal complications, and shortened life-span. Research indicates that one in every 20,000 children in the U.S. is born with the disease.

There is currently no cure for EB, and treatment options are limited, making it a difficult disease for patients and their families to manage.

BPGbio’s Clinical Trial for EB

BPGbio completed phase 1 study for BPGbio’s EB Drug Candidate BPM 31510 in late 2019 and is currently working on advancing to the next phase of clinical development.

• Preliminary evidence from Phase 1 clinical trial suggests BPGbio’s BPM31510 appears to be well tolerated and also potentially efficacious in improving wound healing.
• Preclinical data demonstrates that BPGbio’s BPM31510 influences several components of wound healing pathways to help in the treatment of wounds.

BPGbio’s Epidermolysis Bullosa drug candidate (BPM31510) received FDA Orphan-Drug Designation in May 2018.

BPGbio received FDA Rare Pediatric Disease Designation for its Investigational Treatment for Epidermolysis Bullosa.

For more information about BPGbio’s BPM31510 Epidermolysis Bullosa (EB) trial, please click here.

How does BPGbio’s (BERG) BPM 31510 for Epidermolysis Bullosa (EB)  treatment work?

BPGbio’s BPM31510 is a novel molecule that specially targets the mitochondria to influence the metabolism of cells. BPGbio’s BPM 31510 effects on metabolism result in the normalization/reactivation of pathways that detect cellular dysfunction and damage – shifting biology towards normal.

EB Specific Treatment

BPGbio’s BPM31510 is in clinical development specifically for wound healing management in all types of EB patients.

Effectiveness and Safety

BPGbio’s BPM31510 acts on the three stages of the wound healing cascade: inflammation, proliferation & remodeling. BPGbio’s BPM31510 has a favorable tolerability profile, as CoQ-10 is a molecule produced naturally in the human body.

Wound Healing Treatment

In the remodeling phases of the wound healing cascade, BPGbio’s BPM31510 influences the expression of structural proteins to potentially strengthen the skin.

Patient Friendly

BPGbio’s BPM31510 is a topical treatment that can be easily applied. The application is painless and comfortable.

BPGbio is currently working on advancing BPM31510 for EB to the next phase of clinical development.

BPGbio has Partnered with debra of America to Support EB Patients and Families

BPGbio has partnered with debra of America to support and advocate on behalf of patients and families affected by EB. debra of America is a non-profit organization that provides comprehensive support to those with epidermolysis bullosa (EB). It is the only national organization in the United States to offer free programs and services to affected individuals and their caregivers and fund research for an EB cure and treatment. By joining forces, we hope to galvanize the disease community and advance treatment research further.

The partnership creates a platform to elevate the EB disease profile by highlighting the potential EB treatments like BPGbio’s BPM31510 at key EB clinical conferences, strengthen EB patient advocacy efforts with Congress, and collaborate with top scientific investigators around the world. To learn more about the partnership, please click here.

In October 2017, BPGbio (then, dba BERG) was honored to be recognized as a Partner in Progress from debra of America.

“As a father of a ten-year-old with a severe form of Epidermolysis Bullosa, and as Executive Director, I want to thank BERG for advancing necessary treatment options for the 25,000 people living in the United States with EB and the nearly 200 children born each year with the disease. debra of America is proud to honor BERG with our Partners in Progress Award for their pioneering approach to drug development and their commitment to improving the quality of life for EB patients and their families.”

– Brett Kopelan, Executive Director of debra of America.

To read more, please click here.